Sklamberg Quoted in Bloomberg Tax on Reauthorization of FDA User Fees
July 21, 2022
Life Sciences & Healthcare Regulatory partner Howard Sklamberg was quoted in the recent Bloomberg Law article, “FDA’s Imperiled Funding Threatens Drug Approval Revamp, Staffing.” The article discusses the growing concerns over reauthorizing FDA user fees. Sklamberg discussed the consequences not reauthorizing user fees, saying that not doing so could cause rippling effects, including disrupting the salaries of FDA employees.
» Read the article (Subscription required).